Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

E-Scape Bio describes new LRRK2 inhibitors

Dec. 5, 2019

Cerevance initiates phase II study of CVN-424 in Parkinson's disease

Dec. 5, 2019

ALS exomes identify new culprit

Dec. 5, 2019

Tiziana begins phase I trial of oral foralumab in healthy volunteers

Dec. 4, 2019

Abide Therapeutics identifies new monoglyceride lipase inhibitors

Dec. 4, 2019

FDA accepts IND for phase I trial of SKL-24741 for epilepsy

Dec. 4, 2019

Study shows how individual brain cell types contribute to AD

Dec. 4, 2019

StemoniX and Atomwise create joint venture that will initially target Rett syndrome

Dec. 4, 2019

AXS-12 achieves primary endpoint in CONCERT phase II study in narcolepsy

Dec. 4, 2019

New Bruton tyrosine kinase inhibitors discovered at Biogen

Dec. 3, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...